Clinical trial NCT05201170: A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye
Official title: A Phase 3, Multi-center, Randomized, Double-Masked and Vehicle-Controlled Study Evaluating the Efficacy and Safety of the Melanocortin, PL9643 Ophthalmic Solution, Compared to Vehicle in Subjects with Dry Eye
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Dry Eye
Dry Eye Syndromes
Keywords: Dry eye
Ophthalmology
Eye diseases
Corneal diseases
Conjunctival diseases
Ophthalmic Solutions
Pharmaceutical Solutions
Lead sponsor: Palatin Technologies, Inc
Sponsor class: INDUSTRY
First posted: 2022-01-21
Enrollment: 575
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Patients will be randomized 1:1 to either the PL9643 treatment group or to the vehicle control group.
Primary purpose: TREATMENT

Brief summary: This is a multi-center, double-masked, randomized, vehicle-controlled study testing PL9643, an ophthalmic solution to determine if safe and efficacious for dry eye patients.

After a 2-week run-in period, patients will be randomized equally to the PL9643 ophthalmic solution or vehicle ophthalmic solution administered bilaterally three times a day for 12 weeks.

A Data Monitoring Committee was engaged to review interim data.

Detailed description: This is a multi-center, double-masked, randomized, vehicle-controlled study testing PL9643, an ophthalmic solution, to determine the safety and efficacy against a vehicle in dry eye patients.

During a 2-week/14-day study run-in period (for the purpose of subject selection) prior to randomization, all subjects will receive Vehicle Ophthalmic Solution (vehicle) bilaterally three times a day. Randomization will then occur in a 1:1 ratio where patients will be assigned to receive PL9643 ophthalmic solution given bilaterally three times a day or vehicle ophthalmic solution administered bilaterally three times a day. The treatment period is 12 weeks.

Eligibility criteria: Inclusion Criteria:

1. Be at least 18 years of age;
2. Provide written informed consent;
3. Be willing and able to comply with all study procedures;
4. Have a patient-reported history of dry eye for at least 5 years prior to Visit 1;
5. Have a history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1;
6. Have a best corrected visual acuity (BCVA) of 0.7 logarithm of the minimum angle of resolution (logMAR) or better (Snellen equivalent score of 20/100 or better) in each eye at Visit 1;
7. Have an inferior fluorescein corneal staining score \> 1 at both Visits 1 and 2 Pre-CAE®;
8. Have an Eye Discomfort from the Visual Analog Scale (VAS) ≥25 at both Visits 1 and 2 Pre-CAE®;
9. Report a score of ≥ 2 according to the Ora Calibra® Ocular Discomfort \& 4-Symptom Questionnaire in at least one of the dry eye symptoms at Visits 1 and 2 Pre-CAE®;
10. Have a Schirmer's Test score of ≤ 10 mm and ≥ 1 mm at Visits 1 and 2;
11. Have a corneal fluorescein staining score of ≥ 2 in any corneal region (inferior, central or superior) according to the Ora Calibra® Corneal and Conjunctival Staining Scale for Grading of Fluorescein Staining in at least one eye at Visits 1 and 2 Pre-CAE®;
12. Have a conjunctival redness score ≥ 1 according to the Ora Calibra® Conjunctival Redness for Dry Eye Scale in at least one eye at Visits 1 and 2 Pre-CAE®;
13. Demonstrate in the same eye(s) a response to the CAE®at Visits 1 and 2 as defined by:

    1. Having at least a ≥1 point increase in fluorescein staining in the inferior region in at least one eye following CAE® exposure;
    2. Reporting an Ocular Discomfort score ≥3 at 2 or more consecutive time points in at least one eye during CAE® exposure (if a subject has an Ocular Discomfort rating of 3 at time = 0 for an eye, s/he must report an Ocular Discomfort rating of 4 for two consecutive measurements for that eye). Note: a subject cannot have an Ocular Discomfort score of 4 at time = 0);
14. Have at least one eye, the same eye, satisfy all criteria for 7, 8, 9, 10, 11, 12 and 13 above;
15. A negative urine pregnancy test if female of childbearing potential (those who are not surgically sterilized \[bilateral tubal ligation, hysterectomy or bilateral oophorectomy\] or post-menopausal \[12 months after last menses\]) and must use adequate birth control through the study period. For non-sexually active females, abstinence may be regarded as an adequate method of birth control

Exclusion Criteria:

1. Have any clinically significant slit-lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction, lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the Investigator may interfere with study parameters;
2. Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1 or Visit 2;
3. Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;
4. Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;
5. Have used Restasis®, Xiidra®, Cequa®, or Eysuvis® within 60 days of Visit 1;
6. Have had any ocular and/or lid surgeries in the past 6 months or have any planned ocular and/or lid surgeries over the study period;
7. Have had any laser procedures (e.g. YAG capsulotomy) in the past 3 months;
8. Be using or anticipate using temporary punctal plugs during the study that have not been stable within 30 days of Visit 1;
9. Be currently taking any topical ophthalmic prescription (including medications for glaucoma) or over-the-counter solutions, artificial tears, gels or scrubs, and cannot discontinue these medications for the duration of the trial (excluding medications allowed for the conduct of the study); the respective wash-out periods are required for thefollowing medications:

   1. Ocular, oral or nasal antihistamines: 72 hours prior to Visit 1 and during the study.
   2. Oral aspirin or aspirin-containing products allowed if dose has been stable over past 30 days prior to Visit 1 and no change in dose is anticipated during the study period
   3. Corticosteroids or mast cell stabilizers (including ocular): 14 days prior to Visit 1
   4. Any medication (oral or topical) known to cause ocular drying that has not been administered as a stable dose for at least 30 days prior to Visit 1 and during the study
   5. All other topical ophthalmic preparations (including artificial tear substitutes) other than the study drops: 72 hours prior to Visit 1
10. Have an uncontrolled systemic disease;
11. Be a woman who is pregnant, nursing, or planning a pregnancy;
12. Be unwilling to submit a urine pregnancy test at Visit 1 and Visit 6 (or early termination visit) if of childbearing potential. Non-childbearing potential is defined as a woman who is permanently sterilized (e.g., bilateral tubal ligation, hysterectomy or bilateral oophorectomy), or is post-menopausal (without menses for 12 consecutive months);
13. Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; intrauterine device; or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use adequate birth control as defined above for the remainder of the study;
14. Have a known allergy and/or sensitivity to the test article or its components;
15. Have a condition or be in a situation which the Investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;
16. Have used an investigational drug or device within 30 days of Visit 1 unless the Investigator or Sponsor deems a washout period of up to 60 days is required;
17. Participated in a previous clinical study involving PL9643;
18. Be unable or unwilling to follow instructions, including participation in all study assessments and visits.

Primary outcomes:
measure: Conjunctival Sum Lissamine Green Staining
timeFrame: Visit 6 (Day 85), Change from Pre-CAE to Post-CAE
measure: Ocular Pain
timeFrame: Change from Pre-CAE to Post-CAE at Visit 6 (Day 85)
Secondary outcomes:
measure: Nasal Lissamine Green Staining in Study Eye
timeFrame: Change from Baseline to Visit 6 (Day 85), Pre-CAE
measure: Tear Film Break-Up Time (TFBUT) in Study Eye
timeFrame: Change from Baseline to Visit 6 (Day 85), Post-CAE
measure: Total Sum Lissamine Green Staining in Study Eye
timeFrame: Change from Baseline Pre-CAE® to Week 12 Pre-CAE
measure: Ocular Pain for ITT
timeFrame: Visit 6 (Day 85), Change from Pre-CAE to Post-CAE
measure: Inferior Fluorescein Staining in Study Eye
timeFrame: Change from Baseline to Visit 6 (Day 85), Post-CAE
measure: Inferior Corneal Fluorescein Staining in Study Eye
timeFrame: Change from Baseline to Visit 6 (Day 85), Pre-CAE
measure: Foreign Body Sensation for Hyper-Responders
timeFrame: Visit 6 (Day 85), Change from Pre-CAE to Post-CAE
measure: Eye Dryness for Hyper-Responders versus Vehicle in hyper-responder sub-population
timeFrame: Change from Baseline to Visit 6 (Day 85), Post-CAE
measure: Unanesthetized Schirmer Test Result (mm) in Study Eye
timeFrame: Change from Baseline to Visit 6 (Day 85), Pre-CAE
measure: Eye Discomfort for Hyper-responders versus Vehicle in hyper-responder sub-population
timeFrame: Change from Baseline to Visit 6 (Day 85), Post-CAE
Other outcomes:
measure: Pain for Hyper-Responders
timeFrame: Change from Baseline to Visit 3 (Day 15), Post-CAE
measure: Pain for ITT
timeFrame: Visit 3 (Day 15), Change from Pre-CAE to Post-CAE
measure: Eye Discomfort for Hyper-responders
timeFrame: Visit 3 (Day 15), Change from Pre-CAE to Post-CAE
Locations:
city: Glendale
country: United States
facility: Global Research Management
state: California
city: Newport Beach
country: United States
facility: Eye Research Foundation
state: California
city: Torrance
country: United States
facility: East West Eye Institute
state: California
city: Columbus
country: United States
facility: Pankratz Eye Institute
state: Indiana
city: Indianapolis
country: United States
facility: Michael Washburn Center for Ophthalmic Research, LLC
state: Indiana
city: Lexington
country: United States
facility: Kentucky Eye Institute
state: Kentucky
city: Louisville
country: United States
facility: Butchertown Clinical Trials
state: Kentucky
city: Andover
country: United States
facility: Andover Eye Associates
state: Massachusetts
city: Las Vegas
country: United States
facility: Center for Sight
state: Nevada
city: Mint Hill
country: United States
facility: Mint Hill
state: North Carolina
city: Shelby
country: United States
facility: Core, Inc
state: North Carolina
city: Fargo
country: United States
facility: Bergstrom Eye research, LLC
state: North Dakota
city: Erie
country: United States
facility: Erie Retina Research, LLC
state: Pennsylvania
city: Goodlettsville
country: United States
facility: Advancing Vision Research
state: Tennessee
city: Memphis
country: United States
facility: Total Eye Care, PA
state: Tennessee
city: Smyrna
country: United States
facility: Advancing Vision Research
state: Tennessee
city: Austin
country: United States
facility: Austin Clinical Research
state: Texas
city: Dallas
country: United States
facility: Axis Clinical
state: Texas
Study officials:
affiliation: Palatin
name: Brian Dodge
role: STUDY_DIRECTOR
References: